{"id":"NCT02763319","sponsor":"Incyte Corporation","briefTitle":"A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","officialTitle":"A Phase 2/3, Randomised, Multicentre Study of Tafasitamab With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-11-28","primaryCompletion":"2024-06-21","completion":"2024-06-21","firstPosted":"2016-05-05","resultsPosted":"2025-07-17","lastUpdate":"2025-07-17"},"enrollment":453,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Diffuse Large B-cell Lymphoma"],"interventions":[{"type":"DRUG","name":"Rituximab (RTX)","otherNames":["Rituxan","Mab Thera"]},{"type":"DRUG","name":"Tafasitamab","otherNames":[]},{"type":"DRUG","name":"Bendamustine (BEN)","otherNames":["Levact/Treanda"]}],"arms":[{"label":"Tafasitamab and bendamustine","type":"EXPERIMENTAL"},{"label":"Rituximab and bendamustine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.","primaryOutcome":{"measure":"Kaplan-Meier Estimate of Progression-Free Survival by Independent Radiology/Clinical Review Committee Assessment in the Overall Population","timeFrame":"up to 41.4 months","effectByArm":[{"arm":"Tafasitamab + Bendamustine","deltaMin":7.1,"sd":null},{"arm":"Rituximab + Bendamustine","deltaMin":8.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.468"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":158,"countries":["United States","Australia","Austria","Canada","Croatia","Czechia","Finland","France","Germany","Hungary","Israel","Italy","New Zealand","Poland","Portugal","Romania","Serbia","Singapore","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":115,"n":219},"commonTop":["Neutropenia","Nausea","Thrombocytopenia","Anaemia","Diarrhoea"]}}